Teva Pharmaceutical Industries Ltd. (TEVA) said that the U.S. Food and Drug Administration has granted final approval for the company's Abbreviated New Drug Application to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid or lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. The company said the customers would begin receiving product on November 11, 2009.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is a generic pharmaceutical company.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.